Literature DB >> 3619421

Effect of dose on pharmacokinetics and serum bactericidal activity of mezlocillin.

J F Flaherty, S L Barriere, J Mordenti, J G Gambertoglio.   

Abstract

Mezlocillin is subject to dose-dependent pharmacokinetics. Previous studies have examined the pharmacokinetic but not the pharmacodynamic aspects of this effect. The pharmacokinetic disposition of mezlocillin was determined in eight healthy volunteers in a randomized, crossover fashion after single infusions of 50 and 80 mg of mezlocillin per kg of body weight. Plasma and urine were assayed with a specific high-pressure liquid chromatography assay and analyzed by noncompartmental methods. Pharmacodynamic (bactericidal) effects were evaluated from serial serum bactericidal titers obtained after each dose by using the area under the bactericidal activity curve method. The mean mezlocillin total body clearance decreased from 203.6 +/- 36.2 ml/min after the 50-mg/kg dose to 171.7 +/- 42.1 ml/min after the 80-mg/kg dose (P, 0.01). The decreased clearance was reflected by a decrease in nonrenal clearance only (108.9 +/- 20.0 to 77.9 +/- 23.5 ml/min, respectively; P, 0.001). Mean areas under the curve for concentration in plasma versus time normalized to the 50-mg/kg dose were 314 +/- 73 and 375 +/- 64 micrograms X h/ml for the low and high doses, respectively (P, 0.01). No significant changes were observed in the steady-state volume of distribution or elimination half-life. Mean areas under the bactericidal activity curve were 100 +/- 77 and 244 +/- 143 for the 50- and 80-mg/kg doses, respectively. The decrease in mezlocillin clearance and the disproportionate increase in the area under the curve for concentration in plasma versus time, coupled with the observed prolonged bactericidal effects of the 80-mg/kg dose, lend support for administration of mezlocillin at a higher dose less frequently (e.g., 5 g every 8 h). Clinical trials with the higher-dose regimen are warranted to validate these observations.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3619421      PMCID: PMC284206          DOI: 10.1128/AAC.31.6.895

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  10 in total

1.  Analysis of a new method for assessing activity of combinations of antimicrobials: area under the bactericidal activity curve.

Authors:  S L Barriere; E Ely; J E Kapusnik; J G Gambertoglio
Journal:  J Antimicrob Chemother       Date:  1985-07       Impact factor: 5.790

2.  Dose-dependent pharmacokinetics of mezlocillin in subjects with normal and impaired renal function.

Authors:  A Mangione; D M Janicke; F D Boudinot; R M Schultz; W J Jusko
Journal:  J Antimicrob Chemother       Date:  1982-01       Impact factor: 5.790

3.  Serum dilution test for bactericidal activity. II. Standardization and correlation with antimicrobial assays and susceptibility tests.

Authors:  L B Reller; C W Stratton
Journal:  J Infect Dis       Date:  1977-08       Impact factor: 5.226

4.  Dynamic interaction between disulfiram and separated enantiomorphs of racemic warfarin.

Authors:  R A O'Reilly
Journal:  Clin Pharmacol Ther       Date:  1981-03       Impact factor: 6.875

5.  Pharmacokinetics of mezlocillin in healthy volunteers.

Authors:  T Bergan
Journal:  Antimicrob Agents Chemother       Date:  1978-12       Impact factor: 5.191

6.  Comparative pharmacokinetics of two multiple-dose mezlocillin regimens in normal volunteers.

Authors:  P A Colaizzi; A A Coniglio; W J Poynor; N Vishniavsky; H T Karnes; R E Polk
Journal:  Antimicrob Agents Chemother       Date:  1986-11       Impact factor: 5.191

7.  In vitro activity of mezlocillin and its related compounds against aerobic and anaerobic bacteria.

Authors:  H Thadepalli; I Roy; V T Bach; D Webb
Journal:  Antimicrob Agents Chemother       Date:  1979-03       Impact factor: 5.191

8.  Mezlocillin in the therapy of serious infections.

Authors:  S J Pancoast; J A Jahre; H C Neu
Journal:  Am J Med       Date:  1979-11       Impact factor: 4.965

9.  Mezlocillin dose dependent elimination kinetics in renal impairment.

Authors:  G R Aronoff; R S Sloan; R A Stanish; N S Fineberg
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

10.  Prednisolone pharmacodynamics assessed by inhibition of the mixed lymphocyte reaction.

Authors:  B M Frey; F J Frey; N H Holford; F Lozada; L Z Benet
Journal:  Transplantation       Date:  1982-06       Impact factor: 4.939

  10 in total
  7 in total

Review 1.  Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: kill curves versus MIC.

Authors:  Markus Mueller; Amparo de la Peña; Hartmut Derendorf
Journal:  Antimicrob Agents Chemother       Date:  2004-02       Impact factor: 5.191

2.  Effect of protein binding on serum bactericidal activities of ceftazidime and cefoperazone in healthy volunteers.

Authors:  Y W Lam; M H Duroux; J G Gambertoglio; S L Barriere; B J Guglielmo
Journal:  Antimicrob Agents Chemother       Date:  1988-03       Impact factor: 5.191

3.  Pharmacokinetics and pharmacodynamics of two multiple-dose piperacillin-tazobactam regimens.

Authors:  D J Occhipinti; S L Pendland; L L Schoonover; E B Rypins; L H Danziger; K A Rodvold
Journal:  Antimicrob Agents Chemother       Date:  1997-11       Impact factor: 5.191

Review 4.  Basis of anti-infective therapy: pharmacokinetic-pharmacodynamic criteria and methodology for dual dosage individualisation.

Authors:  A Sánchez-Navarro; M M Sánchez Recio
Journal:  Clin Pharmacokinet       Date:  1999-10       Impact factor: 6.447

5.  Population pharmacokinetics of piperacillin at two dose levels: influence of nonlinear pharmacokinetics on the pharmacodynamic profile.

Authors:  Cornelia B Landersdorfer; Jurgen B Bulitta; Carl M J Kirkpatrick; Martina Kinzig; Ulrike Holzgrabe; George L Drusano; Ulrich Stephan; Fritz Sörgel
Journal:  Antimicrob Agents Chemother       Date:  2012-08-20       Impact factor: 5.191

6.  Comparative pharmacokinetics and serum inhibitory activity of clindamycin in different dosing regimens.

Authors:  J F Flaherty; L C Rodondi; B J Guglielmo; J C Fleishaker; R J Townsend; J G Gambertoglio
Journal:  Antimicrob Agents Chemother       Date:  1988-12       Impact factor: 5.191

Review 7.  Pulse dosing versus continuous infusion of antibiotics. Pharmacokinetic-pharmacodynamic considerations.

Authors:  M LeBel; M Spino
Journal:  Clin Pharmacokinet       Date:  1988-02       Impact factor: 6.447

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.